{"DataElement":{"publicId":"4379840","version":"1","preferredName":"Laboratory Procedure Alkaline Phosphatase Measurement SGOT (AST) SGPT (ALT) Eligibility Determination Code Indicator","preferredDefinition":"The coded yes/no/not applicable indicator related to criteria to determine eligibility of patients for medical care programs and services for any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting of measurement of serum glutamate pyruvate transaminase, serum glutamic-oxaloacetic transaminase or alkaline phosphatase present in a sample.","longName":"LAB_AST_ALT_COD_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"3257654","version":"1","preferredName":"Laboratory Procedure Alkaline Phosphatase Measurement SGOT (AST) SGPT (ALT) Eligibility Determination","preferredDefinition":"information related to criteria to determine eligibility of patients for medical care programs and services for any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting of measurement of serum glutamate pyruvate transaminase, serum glutamic-oxaloacetic transaminase or alkaline phosphatase present in a sample.","longName":"2543047v1.0:3257652v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2543047","version":"1","preferredName":"Test","preferredDefinition":"A procedure for critical evaluation; a means of determining the presence, quality, or truth of something.","longName":"C25294","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Laboratory Procedure","conceptCode":"C25294","definition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2262D258-9F2F-4D98-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-11-16","modifiedBy":"ONEDATA","dateModified":"2006-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3257652","version":"1","preferredName":"Alkaline Phosphatase Measurement SGOT (AST) SGPT (ALT) Eligibility Determination","preferredDefinition":"A quantitative measurement of alkaline phosphatase present in a sample.:Activity measured as a test of liver function, 46/47-kDa homodimeric human Aspartate Aminotransferases (Class-I Pyridoxal-Phosphate-Dependent Aminotransferase Family) are pyridoxal phosphate-dependent enzymes involved in amino acid metabolism and in the urea and tricarboxylic acid cycles. (NCI):Activity measured as a test of liver function, human Glutamic-Pyruvate Transaminases (Alanine Aminotransferase Family) are pyridoxal phosphate-dependent enzymes involved in cellular nitrogen metabolism, amino acid metabolism, and liver gluconeogenesis. Glutamic Pyruvic Transaminases mediate conversion of major intermediate metabolites, catalyzing reversible transamination between alanine and alpha-ketoglutarate to form pyruvate and glutamate. (NCI):Criteria to determine eligibility of patients for medical care programs and services.","longName":"C64432:C25202:C25293:C25171","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alkaline Phosphatase Measurement","conceptCode":"C64432","definition":"A quantitative measurement of alkaline phosphatase present in a sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Aspartate Aminotransferase","conceptCode":"C25202","definition":"A family of pyridoxal phosphate-dependent enzymes involved in amino acid metabolism and in the urea and tricarboxylic acid cycles. Aspartate aminotransferase specifically and reversibly catalyzes the transfer of an amino group from L-aspartate to alpha-ketoglutarate forming oxaloacetate and L-glutamate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Alanine Aminotransferase","conceptCode":"C25293","definition":"A family of pyridoxal phosphate-dependent enzymes involved in cellular nitrogen metabolism, amino acid metabolism, and liver gluconeogenesis. Alanine aminotransferase specifically and reversibly catalyzes the transfer of an amino group from L-alanine to alpha-ketoglutarate forming pyruvate and L-glutamate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Eligibility Determination","conceptCode":"C25171","definition":"The act of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8FD5CDF-1741-4835-E040-BB89AD43041C","latestVersionIndicator":"Yes","beginDate":"2011-07-26","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-07-26","modifiedBy":"ONEDATA","dateModified":"2011-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8FD5CDF-1752-4835-E040-BB89AD43041C","latestVersionIndicator":"Yes","beginDate":"2011-07-26","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-07-26","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876352","version":"1","longName":"Inclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876425","version":"1","longName":"Laboratory Data (including serologic/viral status)","context":"Theradex"}]},{"publicId":"3876594","version":"1","longName":"Theradex","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876603","version":"1","longName":"Theradex - CTMS 3.14","context":"Theradex"}]}],"AlternateNames":[{"name":"LAB_AST_ALT_COD_IND","type":"USED_BY","context":"Theradex"}],"ReferenceDocuments":[{"name":"Theradex - 3","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 3 x institutional upper limit of normal?","url":null,"context":"Theradex"},{"name":"Are pre-study AST (SGOT), ALT","type":"Preferred Question Text","description":"Are pre-study AST (SGOT), ALT (SGPT) and alkaline phosphatase less than or equal to 2.5 x upper limit of normal or less than or equal to 5 x upper limit of normal if liver involvement?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 2.5 x upper limit of normal or less than or equal to 5 x upper limit of normal  for patients with liver metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"Are pre-study AST and ALT less than or equal to 2.5 x institutional upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 2.5 x upper limit of normal or less than or equal to 5 x upper limit of normal for patients with metastatic liver disease?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than 3 x institutional upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"Is pre-study ALT (SGPT) less than 2.5 x upper limit of normal (ULN), OR less than 5 x ULN in the presence of liver metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"Is pre-study ALT (SGPT) or AST (if available at center) less than 2.5 x upper limit of normal (ULN), OR less than 5 x ULN in the presence of liver metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 2.5 x institutional upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"Are pre-study AST (SGOT), ALT (SGPT) and alkaline phosphatase less than or equal to 3 x upper limit of normal or less than 5 x upper limit of normal in patients with Gilbert's disease?","url":null,"context":"Theradex"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 2.5 x upper limit of normal or less than or equal to 5 x upper limit of normal for patients with liver involvement?","url":null,"context":"Theradex"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"Are pre-study AST (SGOT), ALT (SGPT) and alkaline phosphatase less than or equal to 3 x upper limit of normal or less than or equal to 5 x upper limit of normal in patients with Gilbert's disease?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"Are pre-study AST and ALT less than 2.5 x institutional upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than 2 x upper limit of normal or less than 5 x upper limit of normal for patients with liver involvement?","url":null,"context":"Theradex"},{"name":"Theradex - 17","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than 2 x upper limit of normal or less than 5 x upper limit of normal if liver metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 18","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 2 x institutional upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 16","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 2 x upper limit of normal or less than or equal to 5 x upper limit of normal for patients with liver metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 19","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 3 x upper limit of normal or less than or equal to 5 x upper limit of normal for patients with liver metastases? ","url":null,"context":"Theradex"},{"name":"Theradex - 20","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 3 x upper limit of normal (AST and/or ALT less than or equal to 5 x upper limit of normal for patients with liver involvement)?","url":null,"context":"Theradex"},{"name":"Theradex - 21","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 3 x upper limit of normal or less than or equal to 5 x upper limit of normal for patients with liver involvement?","url":null,"context":"Theradex"},{"name":"Theradex - 22","type":"Alternate Question Text","description":"Are pre-study AST and ALT less than or equal to 3 x institutional upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 23","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 5 x institutional upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 24","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 1.5 x institutional upper limit of normal (AST and/or ALT less than or equal to 3 x ULN for patients with liver involvement)?","url":null,"context":"Theradex"},{"name":"Theradex - 26","type":"Alternate Question Text","description":"Are pre-study AST(SGOT)/ALT(SGPT) less than or equal to 2.5 x institutional upper limit of normal if no demonstrable liver metastases or less than or equal to 5 x institutional upper limit of normal in the presence of liver metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 25","type":"Alternate Question Text","description":"Are pre-study SGPT (ALT) or SGOT (AST) less than or equal to 2.5 x the upper limit of normal in the absence of hepatic metastases; SGPT (ALT) less than or equal to 3 x ULN or SGOT (AST) less than or equal to 5 x ULN in the presence of hepatic metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 27","type":"Alternate Question Text","description":"Is pre-study ALT less than or equal to 3.0 x upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 43","type":"Alternate Question Text","description":"Are pre-study AST (SGOT), ALT (SGPT) and alkaline phosphatase less than or equal to 3 x upper limit of normal within 2 weeks of randomization?","url":null,"context":"Theradex"},{"name":"Theradex - 29","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 3 x upper limit of normal or less than or equal to 5 x upper limit of normal for patients with known hepatic metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 30","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than 2 x upper limit of normal or less than 5 x upper limit of normal for patients known to have liver metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 28","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 2.5 x upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 42","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 2.5 x institutional upper limit of normal or less than or equal to 5.0 x institutional upper limit of normal (only if elevated LFTs are due to disease)?","url":null,"context":"Theradex"},{"name":"Theradex - 45","type":"Alternate Question Text","description":" Are pre-study AST (SGOT)/ALT (SGPT) less than 3 x upper limit of normal or less than to 5 x upper limit of normal for patients with liver metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 47","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 2.5 x institutional upper limit of normal or less than or equal to 5 x upper limit of normal for patients with liver metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 38","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than 2 x upper limit of normal or less than 5 x upper limit of normal for patients known to have liver metastasest?","url":null,"context":"Theradex"},{"name":"Theradex - 37","type":"Alternate Question Text","description":"Is pre-study aspartate transaminase (AST) less than or equal to 2.5 x upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 46","type":"Alternate Question Text","description":"Is pre-study creatinine clearance greater than or equal to 30 mL/min/1.73 m2 by Cockcroft-Gault or creatinine less than 1.5 x upper limit of normal, within 2 weeks of randomization?","url":null,"context":"Theradex"},{"name":"Theradex - 44","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 2.5 x institutional upper limit of normal if no demonstrable liver metastases or less than or equal to 5 x upper limit of normal for patients with liver metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 39","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 3 x institutional upper limit of normal or less than or equal to 5 x institutional upper limit of normal for patients with liver metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 40","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 1.5 x upper limit of normal or less than or equal to 2.5 x upper limit of normal for patients with liver metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 48","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 3 x upper limit of normal, within 2 weeks of randomization?","url":null,"context":"Theradex"},{"name":"Theradex - 49","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 1.5 x institutional upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 50","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 2.5 x upper limit of normal or less than or equal to 5 x upper limit of normal for patients with liver metastases within 28 days prior to administration of therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 51","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 3 x upper limit of normal (AST and/or ALT less than or equal to 5 x upper limit of normal for patients with liver involvement)?","url":null,"context":"Theradex"},{"name":"Theradex - 54","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than 5 x institutional upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 52","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 3 x institutional upper limit of normal or less than or equal to 5 x institutional upper limit of normal for patients with known liver metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 53","type":"Alternate Question Text","description":"Are both pre-study AST (SGOT) and ALT (SGPT) less than 2 x upper limit of normal or less than 5 x upper limit of normal for patients known to have liver metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 56","type":"Alternate Question Text","description":"Are pre-study AST(SGOT)/ALT(SGPT) less than or equal to 2.5 x institutional upper limit of normal (less than or equal to 5 x institutional upper limit of normal for patients with liver involvement), within 7 days before starting treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 57","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 2.5 x institutional upper limit of normal or less than or equal to 5 x upper limit of normal for patients with liver metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 59","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 2.5 x institutional upper limit of normal or less than or equal to 5 x institutional upper limit of normal for patients with liver metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 58","type":"Alternate Question Text","description":"Are pre-study AST (SGOT) and ALT (SGPT) less than 3 x upper limit of normal or less than to 5 x upper limit of normal for patients with liver metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 60","type":"Alternate Question Text","description":"Are screening visit AST (SGOT)/ALT (SGPT) less than or equal to 3 x ULN (AST and/or ALT less than or equal to 5 x ULN for patients with liver involvement)?","url":null,"context":"Theradex"},{"name":"Theradex - 61","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 2.5 x institutional upper limit of normal, unless thought to be related to the underlying disease?","url":null,"context":"Theradex"},{"name":"Theradex - 65","type":"Alternate Question Text","description":"Are pre-study AST(SGOT)/ALT(SGPT) less than or equal to 2.5 x institutional ULN, or less than 5 x ULN if due to leukemia?","url":null,"context":"Theradex"},{"name":"Theradex - 62","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 2.5 x institutional upper limit of normal or less than or equal to 5 x upper limit of normal for patients with liver involvement?","url":null,"context":"Theradex"},{"name":"Theradex - 64","type":"Alternate Question Text","description":"Are pre-study AST(SGOT)/ALT(SGPT) less than or equal to 5 x institutional ULN or less than 8 x institutional ULN for patients with liver metastases or an autoimmune disease that is contributing to the elevation of these values?","url":null,"context":"Theradex"},{"name":"Theradex - 66","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 3 x institutional upper limit of normal (ULN)?","url":null,"context":"Theradex"},{"name":"Theradex - 55","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 2.5 x institutional upper limit of normal or less than or equal to 5 x upper limit of normal for patients with liver metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 68","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 3 x institutional upper limit of normal or less than or equal to 5 x institutional upper limit of normal for patients with liver involvement?","url":null,"context":"Theradex"},{"name":"Theradex - 140","type":"Alternate Question Text","description":"Are pre-study AST(SGOT)/ALT(SGPT) less than or equal to ≤3 x institutional upper limit of normal (unless resulting from liver infiltration with leukemia)?","url":null,"context":"Theradex"},{"name":"Theradex- 70","type":"Alternate Question Text","description":"Are pre-study AST(SGOT)/ALT(SGPT) less than or equal to ≤3 x institutional upper limit of normal (unless resulting from liver infiltration with leukemia)?","url":null,"context":"Theradex"},{"name":"Theradex - 67","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 2.5 x institutional ULN, unless considered due to organ leukemic involvement or if liver metastasis are present, less than or equal to 5 x ULN?","url":null,"context":"Theradex"},{"name":"Theradex - 71","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 2.5 x upper limit of normal or less than or equal to 5 x upper limit of normal for patients with hepatobiliary tumors/liver metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 63","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 3 x institutional upper limit of normal (for patients with liver infiltration with leukemia, are pre-study AST(SGOT)/ALT(SGPT) less than or equal to 5 x institutional upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 141","type":"Alternate Question Text","description":"Are pre-study AST (SGOT) and ALT (SGPT) less than or equal to 2.5 x upper limit of normal or less than or equal to 5 x upper limit of normal for patients with liver metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 143","type":"Alternate Question Text","description":"Are pre-study AST(SGOT)/ALT(SGPT) less than or equal to 3 x institutional upper limit of normal OR less than or equal to 5 x institutional upper limit of normal for patients with liver metastases at baseline, within 8 days of enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 145","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 3 x institutional ULN?","url":null,"context":"Theradex"},{"name":"Theradex - 142","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 2.5 x upper limit of normal or less than or equal to 5 x upper limit of normal for patients with liver metastases (within 7 days of study drug initiation)?","url":null,"context":"Theradex"},{"name":"Theradex - 154","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 3 x institutional upper limit of normal within 14 days prior to enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 146","type":"Alternate Question Text","description":"Are pre-study AST(SGOT)/ALT(SGPT) less than or equal to 2.5 x institutional upper limit of normal (less than or equal to 5 x ULN if liver infiltration with leukemia)?","url":null,"context":"Theradex"},{"name":"Theradex - 147","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 3 x institutional upper limit of normal (AST and/or ALT less than or equal to 5 x upper limit of normal for patients with liver involvement)?","url":null,"context":"Theradex"},{"name":"Theradex - 148","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 3 x institutional ULN or less than or equal to 5 x ULM if liver metastases are present?","url":null,"context":"Theradex"},{"name":"Theradex - 69","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 3 x institutional upper limit of normal (ULN) or less than or equal to 5 x upper limit of normal for patients with metastatic liver disease?","url":null,"context":"Theradex"},{"name":"Theradex - 149","type":"Alternate Question Text","description":"Are pre-study AST(SGOT)/ALT (SGPT) less than or equal to 2.5 x institutional ULN?","url":null,"context":"Theradex"},{"name":"Theradex - 150","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 3 x institutional upper limit of normal or less than or equal to 5 x upper limit of normal for patients with liver metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 151","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 3 x ULN within 14 days of randomization/enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 152","type":"Alternate Question Text","description":"Is pre-study AST(SGOT)/ALT(SGPT) less than or equal to 5 x institutional upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 15","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal 3 x institutional upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 153","type":"Alternate Question Text","description":"Are pre-study AST (SGOT)/ALT (SGPT) less than or equal to 2.5 x institutional ULN for age?","url":null,"context":"Theradex"},{"name":"Theradex - 155","type":"Alternate Question Text","description":"Are pre-study AST(SGOT)/ALT (SGPT) within 2 weeks of enrollment less than or equal to 2.5 x institutional ULN?","url":null,"context":"Theradex"},{"name":"Theradex - 157","type":"Alternate Question Text","description":"Are pre-study AST(SGOT)/ALT(SGPT) less than or equal to 3 x institutional upper limit of normal OR less than or equal to 5 x institutional upper limit of normal for patients with liver metastases at baseline?","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD3AFC98-6B68-D1F7-E040-BB89AD432DC8","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-07-02","modifiedBy":"SOKKERL","dateModified":"2023-10-23","changeDescription":"Theradex_ghd_07-02-14 Removed duplicate AQT per LK. AK","administrativeNotes":"2022.8.10 Corrected special character in AQT. Ticket CADSR0001350. ak","unresolvedIssues":null,"deletedIndicator":"No"}}